Novo launches $249 Wegovy subscription, undercutting Lilly as shares fall 30% - Yahoo Finance
Corroborated by 4 sources from 4 publishers
TL;DR
Reports differ across sources; according to cnbc.com, inability to stay on GLP-1s is a longstanding issue due to factors such as difficulty accessing the drugs and gastrointestinal side effects, with one 2025 study estimating that around 65% of patients with obesity stop treatment within a year.
Sources
1
Bloomberg Industries
https://www.bloomberg.com/news/articles/2026-03-31/novo-bets-subscriptions-will-offer-an-edge-in-obesity-drug-sales
2
Bloomberg Industries
https://www.bloomberg.com/news/articles/2026-03-31/novo-nordisk-india-cuts-prices-of-weight-loss-diabetes-drugs
3
The Wall Street Journal
https://www.wsj.com/health/pharma/novo-nordisk-launches-discounted-subscription-program-for-wegovy-obesity-drugs-af810920
4
FiercePharma
https://www.fiercepharma.com/manufacturing/novo-nordisk-cuts-hundreds-roles-troubled-bloomington-site
5
Yahoo Entertainment
https://finance.yahoo.com/sectors/healthcare/articles/novo-launches-249-wegovy-subscription-212341031.html